Fiera Capital Corp Acquires 4,058 Shares of argenex SE $ARGX

Fiera Capital Corp raised its holdings in shares of argenex SE (NASDAQ:ARGX) by 2.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 158,474 shares of the company’s stock after acquiring an additional 4,058 shares during the quarter. Fiera Capital Corp owned approximately 0.26% of argenex worth $87,354,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. WPG Advisers LLC purchased a new position in argenex during the first quarter valued at $37,000. Brooklyn Investment Group raised its stake in shares of argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after buying an additional 38 shares during the period. Banque Transatlantique SA bought a new position in shares of argenex in the first quarter worth about $62,000. Geneos Wealth Management Inc. raised its stake in shares of argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after buying an additional 99 shares during the period. Finally, Raiffeisen Bank International AG purchased a new position in shares of argenex during the 1st quarter valued at about $76,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex Stock Performance

ARGX opened at $889.89 on Thursday. The stock has a market capitalization of $54.79 billion, a price-to-earnings ratio of 38.21, a PEG ratio of 0.91 and a beta of 0.45. The company has a fifty day moving average of $793.04 and a 200 day moving average of $668.78. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $907.47.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating the consensus estimate of $4.37 by $0.03. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. On average, equities research analysts forecast that argenex SE will post 3.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ARGX. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a report on Wednesday, October 8th. Piper Sandler raised their price objective on shares of argenex from $820.00 to $930.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Jefferies Financial Group set a $818.00 target price on shares of argenex and gave the company a “buy” rating in a research note on Tuesday, August 26th. Deutsche Bank Aktiengesellschaft downgraded shares of argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. Finally, Royal Bank Of Canada increased their price target on argenex from $850.00 to $860.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $879.28.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.